A5043373535- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Cancer Cells and Metastasis
- CRISPR and Genetic Engineering
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Gastric Cancer Management and Outcomes
- PI3K/AKT/mTOR signaling in cancer
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Advanced biosensing and bioanalysis techniques
- Renal and related cancers
- BRCA gene mutations in cancer
- Genomic variations and chromosomal abnormalities
- Neuroblastoma Research and Treatments
- Angiogenesis and VEGF in Cancer
- Molecular Biology Techniques and Applications
- SARS-CoV-2 detection and testing
- Genomics and Chromatin Dynamics
- Brain Metastases and Treatment
- Biosensors and Analytical Detection
- Radiomics and Machine Learning in Medical Imaging
Inserm
2008-2024
Université de Rouen Normandie
2013-2024
Normandie Université
2017-2024
Centre Hospitalier Universitaire de Rouen
2022
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2016-2022
Génomique du cancer et du cerveau
2022
Centre Henri Becquerel
2015-2021
Centre Virchow-Villermé
2021
Institute for Research and Innovation in Biomedicine
2013-2017
Purpose: Markers of chemotherapy efficacy in metastatic colorectal cancer (mCRC) are essential for optimization treatment strategies. We evaluated the applicability early changes circulating tumor DNA (ctDNA) as a marker therapeutic efficacy.Experimental Design: This prospective study enrolled consecutive patients with mCRC receiving first- or second-line chemotherapy. CtDNA was assessed plasma collected before first (C0), second (C1) and/or third (C2) cycle, using picodroplet-digital PCR...
The direct comparison of CA19.9, circulating tumour cells (CTCs) and DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis solid pancreatic tumours (SPTs).We included 68 patients with a SPT referred EUS-FNA. CTCs were analysed size-based platform ctDNA digital PCR. sensitivity, specificity, negative positive predictive values evaluated each marker their combination.SPTs corresponded to 58 malignant (52 adenocarcinoma (PA) 6...
// Florian Clatot 1,2,3 , Anne Perdrix 3,4 Laetitia Augusto 1 Ludivine Beaussire 3,5 Julien Delacour Céline Calbrix 4 David Sefrioui 3,5,6 Pierre-Julien Viailly 2 Michael Bubenheim 7 Cristian Moldovan Cristina Alexandru Isabelle Tennevet Olivier Rigal Cécile Guillemet Marianne Leheurteur Sophie Gouérant Camille Petrau 1,3 Jean-Christophe Théry 1,5 Jean-Michel Picquenot 1,2,4 Corinne Veyret Thierry Frébourg 5 Fabrice Jardin Nasrin Sarafan-Vasseur 3,5,* and Frédéric Di Fiore 1,3,5,6,*...
Acquired estrogen receptor gene (ESR1) mutations have been recently reported as a marker of resistance to aromatase inhibitors in hormone positive metastatic breast cancer. We retrospectively considered seven patients treated for cancer with available samples from the primary tumor before any treatment, cryopreserved metastasis removed during progression and concomitant plasmas. All these were disease after previous exposure at least 6 months, assessed ESR1 detection circulating DNA. For...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous malignancy harboring frequent targetable activating somatic mutations. Emerging evidence suggests that circulating cell-free DNA (cfDNA) can be used to detect variants in DLBCL using Next-Generation Sequencing (NGS) experiments. In this proof-of-concept study, we chose develop simple valuable digital PCR (dPCR) assays for the detection of recurrent exportin-1 (XPO1) E571K, EZH2 Y641N, MYD88 L265P mutations patients,...
Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence at end adjuvant treatment by AI early cancer had never been clearly established. In this context, aim present study was evaluate mutation frequency and after relapse. This monocentric retrospective based on available stored plasmas included all patients who completed least 2 years experienced a documented relapse their treatment....
Reverse transcription-quantitative PCR on nasopharyngeal swabs is currently the reference COVID-19 diagnosis method but exhibits imperfect sensitivity.We developed a multiplex reverse transcription-digital droplet (RT-ddPCR) assay, targeting 6 SARS-CoV-2 genomic regions, and evaluated it saliva samples collected from 130 positive or negative ambulatory individuals, who presented symptoms suggestive of mild moderate SARS-CoV2 infection.For swab samples, results obtained using 6-plex RT-ddPCR...
Abstract The clinical implications of plasmatic cell-free and tumor DNA (cfDNA ctDNA) are challenging in glioblastoma. This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma 3) patients treated with concomitant temozolomide radiotherapy (RT-TMZ), followed by a TMZ maintenance phase. Plasma samples were collected at baseline, before RT-TMZ (pre-RT-TMZ) the end adjuvant TMZ, time progression cases progressive disease (PD). cfDNA concentration was...
The most common form of genomic instability observed in colorectal cancer is chromosomal (CIN), whose molecular bases remain to be determined. We have previously demonstrated that inactivation human cells several components the Pes1-Bop1 complex (BOP1, GRWD1, PES1, ORC6L, and RPL3), involved ribosome biogenesis, altered chromosome segregation. To determine contribution tumorigenesis somatic alterations genes we screened 56 primary cancers, using quantitative multiplex PCR short fluorescent...
Abstract Background Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed prospectively compare the risk of early according circulating ESR1 mutations, CA-15.3, and cell-free DNA MBC patients treated with aromatase inhibitor (AI). Methods Patients AI were included. Circulating assessment was performed every 3 months. The primary...
Circulating cell-free DNA (ccfDNA) bears great promise as biomarker for personalized medicine, but ccfDNA is present only at low levels in the plasma or serum of cancer patients. E-ice-COLD-PCR a recently developed enrichment method to detect and identify mutations low-abundance clinical samples. However, recent studies have shown importance accurately quantify clinically important decisions will depend on certain mutation thresholds. The possibility an remains point concern might limit its...
Rare copy number variations (CNVs) are a major cause of genetic diseases. Simple targeted methods required for their confirmation and segregation analysis. We developed simple universal CNV assay based on digital PCR (dPCR) locked nucleic acid (LNA) hydrolysis probes.We analyzed the mapping 90 LNA probes from Roche Universal ProbeLibrary (UPL). For each CNV, selection optimal primers probe was almost automated; were reused across assays dPCR included amplicon reference amplicon. assessed...
Abstract Epidermal growth factor receptor ( EGFR ) amplification and variant III EGFRvIII , deletion of exons 2–7) are clinical interest for glioblastoma. The aim was to develop a digital PCR (dPCR)-based method using locked nucleic acid (LNA)-based hydrolysis probes, allowing the simultaneous detection variant. Sixty-two patients were included. An exploratory cohort n = 19) used dPCR assay three selected amplicons within gene, targeting intron 1 (EGFR1), junction exon 3 (EGFR2) 22 (EGFR3)....
Liquid biopsy application is still challenging in glioblastoma patients and the usefulness of short-length DNA (slDNA) fragments not established. The aim was to investigate slDNA concentration as a prognostic marker unresected patients.
Objective: To investigate in patients treated for a resectable pancreatic ductal adenocarcinoma [pancreatic (PA)], the prognostic value of baseline carbohydrate antigen 19.9 (CA19-9) and circulating tumor DNA (ctDNA) overall survival (OS), to improve death risk stratification, based on planned ancillary study from PANACHE01–PRODIGE 48 trial. Background: Biological borderline situation that was first used by MD Anderson, became standard practice following international consensus conference...
We conducted a prospective study to assess the prognostic impact of selected copy number variations (CNVs) in Stage II-III microsatellite stable (MSS) colon cancer. A total 401 patients were included from 01/2004 01/2009. The CNVs 8 target genes, DCC/18q, EGFR/7p, TP53/17p, BLK/8p, MYC/8q, APC/5q, ERBB2/17q and STK6/20q, detected using quantitative multiplex polymerase chain reaction short fluorescent fragment (QMPSF) method. primary end-point was on 4-year disease-free survival (DFS)....
Abstract Transarterial chemoembolization (TACE) is used to treat patients with unresectable hepatocellular carcinoma (HCC). We evaluated the clinical impact of a‐fetoprotein (AFP) and circulating cell‐free tumor DNA (cfDNA ctDNA) changes around TACE procedure. Our prospective monocentric study enrolled consecutive treated TACE, samples collected at baseline (D − 1), Day 2 + 2) 1 month (M 1) after TACE. cfDNA was quantified by fluorometric method, ctDNA digital polymerase chain reaction...